Disease mechanisms in MS: Phases of disease improvement unrelated to relapses

Nature Reviews Neurology

Volumn 8, Issue 11, 2012, Pages 596-598

  Andersen, Oluf ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IMMUNOMODULATING AGENT;

AGE DISTRIBUTION; BODY TEMPERATURE; BRAIN FUNCTION; BRAIN NERVE CELL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DATA BASE; DEMYELINATION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; MENTAL DEFICIENCY; MULTIPLE SCLEROSIS; NERVE CONDUCTION; NERVE FIBER; NEUROLOGIC EXAMINATION; NEUROPHYSIOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; REMISSION; RISK FACTOR; SCORING SYSTEM; SHORT SURVEY; SYMPTOMATOLOGY; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 84868566976     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.186     Document Type: Short Survey

References (10)

1. Tremlett, H. et al. Natural, innate improvements in multiple sclerosis disability. Mult. Scler. http://dx.doi.org/10.1177/1352458512439119.
2. No authors listed] Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet 2, 179-183 (1988).
3. Jacobs, L. D. et al. Intramuscular interferon beta-1a for disease progression in relapsingYremitting multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285-294 (1996). (Pubitemid 26100751)
4. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon beta 1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon beta 1a in secondary progressive MS. Clinical results. Neurology 56, 1496-1504 (2001).
5. Liu, C. & Blumhardt, L. D. Disability outcome measures in therapeutic trials of relapsingYremitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J. Neurol. Neurosurg. Psychiatry 68, 450-457 (2000). (Pubitemid 30248744)
6. Ebers, G. C., Heigenhauser, L., Saumer, M., Lederer, C. & Noseworthy, J. H. Disability as an outcome in MS clinical trials. Neurology 71, 624-631 (2008).
7. Coles, A. et al. Alemtuzumab versus interferon β-1a in early relapsingYremitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology 10, 338-348 (2011).
8. Albrecht, H. Day to day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter. Mult. Scler. 7, 105-109 (2001). (Pubitemid 32514525)
9. de Weerd, A. W. Variability of central conduction in the course of multiple sclerosis. Clin. Neurol. Neurosurg. 89, 9-15 (1987).
10. Guthri, T. C. & Nelson, D. A. Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. J. Neurol. Sci. 129, 1-8 (1995).